Abstract 2310P
Background
The rapid proliferation of cancer cells leads to abnormal vascularization, creating a hypoxic tumor core in most advanced solid tumors. Recent studies have shown that hypoxia is associated with poor prognosis in cancer patients. Tumor aggressiveness is driven by hypoxia, which confers resistance to many conventional cancer therapies. In the present study, we propose that oxygen nanobubbles can reduce the hypoxic effect on the epithelial-to-mesenchymal transition (EMT) and prevent migration and invasion in non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).
Methods
Using the sonic cavitation method, we have developed a method to generate bulk oxygen nanobubbles (ONBs) with dipalmitoyl phosphatidylcholine (DPPC) lipid and quantitate mean diameter and number density through nanoparticle tracking analysis and insight. We have treated A549 lung adenocarcinoma and MDA-MB-231 triple-negative breast cancer cell lines with 1% oxygen and ONB. We have also checked its preventive role in the zebrafish tumor xenograft model. We have measured HIF-1a and EMT expression markers by immunoblot and qPCR analysis. Moreover, we have used the 4T1 BALB/c mice tumor xenograft model for further confirmation.
Results
ONB promotes HIF-1α hydroxylation and its proteasomal degradation in hypoxic cancer cells. ONBs treated A549 and MDA-MB-231 cancer cells and an adult zebrafish A549 tumor xenografts showed the downregulation of TGF-β and VEGFA expression at the transcriptional and translational levels, which also led to upregulation of epithelial genes like E-cadherin with down-regulation of mesenchymal genes like N cadherin, Vimentin, Fibronectin. ONB treatment significantly affects cancer cell migration. Also, liposomal ONB administrated 4T1 BALB/c breast tumor xenograft model showed similar results.
Conclusions
ONBs reduce HIF-1 mediated epithelial to mesenchymal transition (EMT) controlled by TGF-b and VEGFA and prevent cellular migration and invasion in solid tumors, particularly NSCLC and TNBC. In conclusion, targeted administration of ONB could be a better therapeutic approach to inhibit the hypoxic detrimental effect, which helps to increase the efficacy of anticancer treatments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Department of Science and Technology (DST) Project, India (DSTSERB- ECR/2016/000288Department of Science and Technology (DST) Project, India (DSTSERB- DST (Department of Science and Technology) Project India, ECR/2016/000288.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2262P - Baseline-informed versus tumor-agnostic minimal residual disease (MRD) concordance study in patients with HER2+ gastroesophageal adenocarcinoma patients
Presenter: Pan Du
Session: Poster session 08
2263P - Ethnicity-specific distribution of BRCA1, BRCA2, PALB2 and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus
Presenter: Evgeny Imyanitov
Session: Poster session 08
2264P - Proteomics-based phenotypic classification of non-smallcell lung cancer
Presenter: Olena Berkovska
Session: Poster session 08
2265P - miR-4487 enhances gefitinib-mediated ubiquitination and autophagic degradation of EGFR in non-small cell lung cancer cells by targeting USP37
Presenter: Sei-Hoon Yang
Session: Poster session 08
2266P - IMMUcan consortium: Focus on the first results of the non-small cell lung cancer (NSCLC) cohort
Presenter: Marie Morfouace
Session: Poster session 08
2267P - Coronary heart disease and risk of lung cancer: A two-sample Mendelian randomization study
Presenter: Cai Chen Li
Session: Poster session 08
2269P - Patient derived xenografts generated from circulating cancer stem cells on chorioallantoic membrane as an alternative pre-clinical model for personalized medicine in pancreatic cancer
Presenter: Monika Pizon
Session: Poster session 08
2270P - Integrative analyses of bulk and single-cell RNA-seq identified diabetes mellitus-related signature as a prognostic factor in pancreatic adenocarcinoma
Presenter: Le Tang
Session: Poster session 08
2271P - Development of an oncolytic virus for the treatment of high grade serous ovarian cancer and other stromal rich tumours
Presenter: Miriam Bazan Peregrino
Session: Poster session 08
2272P - Minimal DNA-methylation (DNAm) signatures for non-invasive tumor-agnostic estimation of tumor content (TC) and molecular subtype in patients (pts) with metastatic breast cancer (mBC)
Presenter: Matteo Benelli
Session: Poster session 08